In the context of sensitivity to chemotherapeutic drugs, a specific PDK1 inhibitor termed 2-O-benzyl-myo-inositol 1,3,4,5,6-pentakisphosphate (2-O-Bn-InsP5), had an additive effect in combination with rapamycin and was able to enhance the effect of paclitaxel on SKOV-3 cancer cells. This evidence concerns the gene PDK1 and cancer.